Laxmi Organic Industries (LXCHEM) Q1 25/26 earnings summary

Executive summary

• Q1 FY26 saw an 8% YoY volume increase but a 4% revenue decline, mainly due to lower acetic acid prices, a product phase-out in Specialities, and deferred deliveries shifting some revenue to H2 FY26.

• Essentials segment grew 4% in revenue (11% volume growth), while Specialities declined 18% due to a 9% sales impact from a product phase-out and a 4% impact from deferred deliveries; recovery is expected in H2 FY26.

• Major CapEx projects at Dahej and Lote are progressing on schedule, with Dahej mechanical completion expected by Q3/Q4 FY26 and Lote ramping up fluorination products targeting 40-60% of peak revenues in FY26.

• End-to-end digitization of supply chain operations began in Q1, incurring a one-time expense of INR 79 million, aimed at improving efficiency and cost control.

• The Board approved unaudited standalone and consolidated financial results, reflecting the amalgamation of Yellowstone Fine Chemicals Private Limited and a change in depreciation method.

Financial highlights

• Q1FY26 consolidated revenue was INR 6,929.30 million, down 4% YoY; adjusted EBITDA fell 46% to INR 387 million, and PAT dropped 38% to INR 213.91 million (3.1% margin).

• Essentials segment revenue grew 4% YoY to INR 4,858 million (11% volume growth), while Specialities revenue declined 18% YoY to INR 2,071 million.

• Gross margin declined 470 bps YoY to 30.8%; adjusted EBITDA margin fell 430 bps to 5.6%.

• Cost savings of INR 110 million achieved, mainly from freight and distribution.

• Basic EPS (consolidated) for the quarter was INR 0.77, down from INR 1.24 year-over-year.

Outlook and guidance

• Q2 performance expected to be in line with or better than Q1; Specialities segment to recover in H2 FY26 as deferred deliveries are realized and new products offset phased-out sales.

• The company aims to double consolidated revenue and triple EBITDA by FY28, targeting a combined ROCE of 20%.

• CapEx investment of ~INR 11,000 million is planned to support growth, with a focus on new product launches and wallet expansion.

• Fluorination assets are expected to deliver 40-60% of peak revenues in FY26, with full ramp-up by FY27.